← Back to Clinical Trials
Recruiting NCT06183541

NCT06183541 Effects of Pericapsular Nerve Group Block Applied in Patients Undergoing Hip Fracture Surgery.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06183541
Status Recruiting
Phase
Sponsor Umraniye Education and Research Hospital
Condition Hip Fractures
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2023-11-21
Primary Completion 2025-12-30

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Pericapsular Nerve Group (PENG) Block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2023-11-21 with a primary completion date of 2025-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this study, it was aimed to compare the multimodal analgesia application or the pericapsular nerve group (PENG) block methods in patients undergoing hip surgery. The effectiveness and benefit rate of the PENG block in postoperative pain will be evaluated. Postoperative pain, need for additional analgesia, range of motion of the hip joint, mobilization time, length of hospital time and adverse events in patients undergoing hip fracture surgery with and without PENG block will be investigated.

Eligibility Criteria

Inclusion Criteria: * Patients who will undergo hip fracture surgery Women and men aged 30-85 Exclusion Criteria: * Patients under 30 years old, over 85 years old * American Society of Anesthesiology (ASA) IV, * Those with cognitive impairment (alzheimer, dementia, delirium, etc.) * Those with application site infection * Those who are allergic to local anesthetic substances * Patients are non-consenting patients.

Contact & Investigator

Central Contact

Zeliha Tuncel, MD

✉ zelihalara@yahoo.com

📞 +905053577483

Principal Investigator

Zeliha Tuncel, MD

STUDY DIRECTOR

Umraniye Education and Research Hospita

Frequently Asked Questions

Who can join the NCT06183541 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 85 Years, studying Hip Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06183541 currently recruiting?

Yes, NCT06183541 is actively recruiting participants. Contact the research team at zelihalara@yahoo.com for enrollment information.

Where is the NCT06183541 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye), Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT06183541 clinical trial?

NCT06183541 is sponsored by Umraniye Education and Research Hospital. The principal investigator is Zeliha Tuncel, MD at Umraniye Education and Research Hospita. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology